Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Obstetrics and Gynaecology Canada
- Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.Lancet Oncol. 2008; 9: 425-434
- 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.J Low Genit Tract Dis. 2020; 24: 102-131
- Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.Int J Obstet Gynaecol. 2020; 127: 58-68
- Risk assessment to guide the prevention of cervical cancer.J Low Genit Tract Dis. 2008; 12: 1-7
- A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines.J Low Genit Tract Dis. 2020; 24: 144-147
- Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology.Gynecol Oncol. 2019; 154: 360-367
- Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson Onclarity trial.Am J Clin Pathol. 2019; 151: 53-62
- Management of low-grade cervical cytology in young women. Cohort study from Denmark.Acta Oncol. 2021; 60: 444-451
- Colposcopic episodes of care: referral, treatment, follow-up, and exit patterns of care for women with abnormal pap smears.J Obstet Gynaecol Can. 2014; 36: 1079-1084
- Low risk of cervical cancer/precancer among most women under surveillance postcolposcopy.J Low Genit Tract Dis. 2018; 22: 97-103
- Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.J Low Genit Tract Dis. 2013; 17: S69-S77
Cancer Council Australia. Cervical Cancer Screening Guidelines Working Party. 9. Management of histologically confirmed low-grade squamous abnormalities. Available at: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-of-histologically-confirmed-low-grade-squamous-abnormalities. Accessed on February 4, 2021.
- Cervical screening: colposcopy and programme management.(Available at:)https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/856972/Screening_and_colposcopy_pathways.pdfDate accessed: January 20, 2021
Colposcopic diagnosis, treatment and follow up. Available at: https://www.gov.uk/government/publications/cervical-screening-programme-and-colposcopy-management/3-colposcopic-diagnosis-treatment-and-follow-up. Accessed on February 4, 2021.
- Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines.J Low Genit Tract Dis. 2020; 24: 132-143
- Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.J Low Genit Tract Dis. 2013; 17: S43-S49
- Single negative colposcopy: is it enough to rule out high-grade disease?.J Med Screen. 2011; 18: 160-161
- A prospective follow up study of women with colposcopically unconfirmed positive cervical smears.Br J Obst Gynaecol. 1999; 106: 38-41
- Management of women with low grade cytology: how reassuring is a normal colposcopy examination?.Int J Obstet Gynaecol. 2015; 122: 380-386
- Postcolposcopy management of women with histologically proven CIN 1: results from TOMBOLA.J Low Genit Tract Dis. 2014; 18: 203-209
- A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs.E Clin Med. 2020; 22100293
- Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data.Am J Epidemiol. 2013; 178: 1161-1169
Disclosures: The authors declare they have nothing to disclose.
All authors have indicated they meet the journal’s requirements for authorship.